felin
coronavirus
fcov
belong
genu
alphacoronaviru
famili
coronavirida
ubiquit
viral
pathogen
among
domest
wild
felin
popul
fcov
horizont
transmit
via
fecalor
rout
persist
infect
preval
seroposit
multicat
household
shelter
may
achiev
regard
pathogen
fcov
exist
two
biotyp
name
felin
enter
coronaviru
fecv
felin
infecti
periton
viru
fipv
genet
mutat
occur
fecv
within
persist
infect
cat
allow
acquir
macrophag
tropism
chang
viru
virul
infect
caus
former
show
clinic
appar
mild
selflimit
gastroenter
kitten
contrast
fipv
infect
develop
high
fatal
progress
multisystem
disord
young
cat
popul
felin
infecti
periton
remain
one
devast
lethal
viral
diseas
among
felida
high
mortal
rate
also
lack
effect
option
diagnosi
prevent
diseas
complic
antibodydepend
enhanc
ade
exacerb
diseas
viru
fusion
host
cell
endosom
membran
facilit
low
ph
major
event
certain
viru
infect
vacuolar
atpas
vatpas
activ
respons
pump
proton
endosom
compart
identifi
requir
felin
coronaviru
replic
previou
endosom
acidif
process
also
necessari
establish
ade
fipv
therefor
endosom
vatpas
present
attract
target
antivir
intervent
past
decad
abund
studi
indic
vatpas
inhibitor
could
appli
treat
viral
infect
well
diseas
includ
osteoporosi
lytic
bone
diseas
renal
acidosi
exampl
commonli
use
vatpas
inhibitor
bafilomycin
show
broadspectrum
antivir
effect
sever
pathogen
howev
drug
cytotox
compromis
clinic
recent
diphyllin
natur
compound
extract
plant
cleistanthu
collinu
discov
potent
vatpas
inhibitor
promis
safeti
profil
studi
shown
diphyllin
nanomolar
concentr
inhibit
vatpas
activ
bovin
chromaffin
granul
lysosom
acidif
human
osteoclast
cytotox
effect
bone
studi
treat
gastric
adenocarcinoma
diphyllin
decreas
vatpas
activ
lower
tumor
cell
infect
improv
diseas
previou
studi
also
demonstr
diphyllin
antivir
effect
vitro
influenza
dengu
highlight
compound
potenti
broadspectrum
hosttarget
antivir
present
studi
thu
aim
investig
compound
effect
fipv
drug
safeti
deliveri
critic
factor
determin
antivir
translat
potenti
nanoformul
diphyllin
herein
develop
aim
improv
diphyllin
safeti
efficaci
use
poli
ethylen
glycol
blockpoli
lactidecoglycolid
pegplga
blockcopolym
highli
biocompat
frequent
employ
drug
deliveri
applic
nanocarri
may
benefit
diphyllin
compound
two
way
firstli
hydrophob
core
pegplga
nanocarri
offer
ideal
medium
carri
deliv
hydrophob
diphyllin
compound
obviat
need
organ
solvent
secondli
intracellular
uptak
nanoparticl
via
characterist
endocytosi
mechan
may
enhanc
diphyllin
efficaci
facilit
compound
coloc
endosom
vatpas
therebi
reduc
drug
offtarget
effect
enhanc
antivir
activ
examin
benefit
diphyllin
nanoformul
cellular
cytotox
antivir
activ
free
diphyllin
diphyllin
nanoparticl
compar
addit
vitro
model
fipv
infect
establish
assess
viral
inhibitori
effect
diphyllin
nanoparticl
context
ade
final
safeti
diphyllin
nanoparticl
assess
follow
intraven
inject
mice
blood
chemistri
analysi
bodi
weight
monitor
perform
evalu
drug
safeti
vivo
upon
acridin
orang
label
intracellular
acid
endosom
stain
red
wherea
nonacid
compart
appear
green
fluoresc
microscop
shown
fig
comparison
extens
redstain
endosom
untreat
cell
addit
bafilomycin
diphyllin
show
decreas
number
acid
endosom
increas
number
nonacid
endosom
cell
degre
inhibit
endosom
acidif
shown
correl
diphyllin
concentr
fig
quantit
analyz
endosom
acidif
green
red
fluoresc
data
collect
diphyllintr
well
compar
greenr
fluoresc
ratio
indic
fig
posit
correl
observ
greenr
ratio
diphyllin
concentr
valid
inhibit
endosom
acidif
cell
diphyllin
compound
diphyllin
ad
cell
three
differ
time
point
rel
viru
infect
fig
compar
untreat
control
diphyllin
treatment
infect
result
cytopath
effect
cpe
inhibit
fig
reduc
viral
titer
cultur
supernat
fig
inhibitori
effect
fipv
infect
pronounc
cell
expos
diphyllin
prior
viral
exposur
incub
schedul
also
result
signific
reduct
fipv
titer
therebi
valid
diphyllin
antivir
abil
demonstr
viral
inhibit
activ
diphyllin
immunofluoresc
stain
perform
fitclabel
antibodi
use
detect
fipv
nucleocapsid
protein
fluoresc
microscopi
seen
fig
refer
dapistain
nuclei
cytoplasm
fluoresc
signal
reduc
pretreat
bafilomycin
vari
concentr
diphyllin
dosedepend
inhibitori
effect
fipv
observ
diphyllin
compound
composit
diphyllinload
pegplga
nanoparticl
illustr
fig
examin
format
nanoparticl
tem
analysi
neg
stain
perform
tem
visual
diphyllinload
nanoparticl
fig
observ
uniform
size
averag
diamet
nm
character
nanoparticl
dl
use
analyz
size
distribut
nanoparticl
result
dl
demonstr
diphylinload
nanoparticl
exhibit
averag
particl
diamet
nm
fig
quantif
diphyllin
load
pegplga
nanoparticl
perform
use
hplc
determin
drug
load
yield
effici
present
fig
arrow
peak
elut
diphyllin
observ
min
chromatogram
standard
curv
construct
serial
dilut
sampl
diphylin
separ
correspond
area
valu
mau
second
fig
inset
refer
standard
curv
content
diphyllin
nanoparticl
batch
determin
studi
load
effici
diphyllin
drug
load
yield
wt
cell
viabil
cell
treat
variou
concentr
diphyllin
measur
use
mtt
assay
hr
incub
diphyllin
determin
cell
wherea
diphyllin
nanoparticl
p
fig
indic
reduct
cellular
toxic
nanoformul
reduct
cellular
viabil
observ
empti
nanoparticl
control
concentr
mgml
supplementari
fig
time
higher
highest
diphyllin
nanoparticl
formul
examin
studi
diphyllin
mgml
nanoparticl
result
demonstr
significantli
improv
safeti
profil
diphyllin
nanoparticl
compar
free
diphyllin
formul
assess
diphyllin
variou
nontox
concentr
diphyllin
use
treat
fipv
infect
use
fipv
strain
moi
mtt
assay
perform
examin
cpe
protect
compar
untreat
control
presenc
diphyllin
significantli
inhibit
number
cpe
foci
induc
viral
infect
base
mtt
assay
result
valu
diphyllin
moi
cell
nm
diphyllin
nanoparticl
hand
show
nm
p
fig
correspond
enhanc
antivir
activ
compar
free
drug
empti
pegplga
nanoparticl
show
antivir
effect
mgml
supplementari
fig
calcul
therapeut
index
ti
yield
valu
free
diphyllin
diphyllin
nanoparticl
respect
antivir
activ
diphyllin
diphyllin
nanoparticl
assess
differ
strain
fipv
moi
free
diphyllin
diphyllin
nanoparticl
exhibit
valu
nm
nm
respect
p
fig
enhanc
diphyllin
antivir
efficaci
nanoparticl
also
observ
moi
nm
vs
nm
valu
p
supplementari
fig
valid
nanoformul
greatli
broaden
therapeut
window
compound
light
promis
therapeut
index
diphyllin
nanoparticl
nanoparticl
antivir
activ
examin
fipvinfect
cell
antibodydepend
enhanc
plaqu
assay
conduct
examin
viral
load
cultur
supernat
deriv
two
differ
infect
condit
presenc
absenc
antifipv
mab
indic
fig
presenc
mab
viral
infect
result
signific
increas
viral
titer
pfuml
pfuml
cultur
supernat
cell
infect
fipv
context
ade
antivir
activ
diphyllin
variou
concentr
test
plaqu
assay
hr
incub
observ
diphyllin
reduc
antibodyenhanc
fipv
infect
dosedepend
manner
diphyllin
nanoparticl
treatment
reduc
viral
load
order
magnitud
pfuml
result
highlight
promis
diphyllin
nanoparticl
address
seriou
immunopatholog
complic
fipv
infect
assess
safeti
diphyllin
nanoparticl
vivo
blood
chemistri
analysi
bodi
weight
monitor
perform
mice
treat
nanoformul
mgml
diphyllin
nanoparticl
diphyllin
intraven
given
balbc
mice
twice
day
day
blood
draw
perform
day
nanoparticl
administr
day
day
blood
chemistri
analysi
show
mani
paramet
includ
total
protein
blood
urea
nitrogen
bun
creatinin
affect
nanoparticl
administr
fig
aspart
transaminas
ast
alanin
transaminas
alt
observ
elev
follow
treatment
remain
within
normal
fig
e
diphyllin
nanoparticl
found
decreas
level
alkalin
phosphatas
alp
day
effect
transient
alp
level
recov
day
fig
monitor
bodi
weight
show
littl
weight
chang
among
treat
anim
day
fig
overal
diphyllin
nanoparticl
well
toler
test
anim
show
sign
distress
observ
fcov
infect
common
young
cat
infect
cat
may
develop
date
fip
remain
fatal
case
lack
effect
prophylact
therapeut
treatment
option
clinic
set
recommend
diseas
manag
fip
manifest
includ
varieti
support
treatment
immunomodulatori
drug
antibiot
anticoagul
fluid
studi
shown
diseas
sever
correl
system
viral
henc
antivir
therapeut
reduc
viral
spread
may
benefici
toward
diseas
control
previous
coronavir
proteas
inhibitor
demonstr
promis
advanc
direct
inhibit
viru
replic
clinic
pathogentarget
antivir
approach
test
vitro
await
efficaci
valid
vivo
among
differ
antivir
strategi
hosttarget
therapeut
increasingli
recogn
attract
antivir
treatment
approach
exert
direct
select
pressur
viral
pathogen
advantag
hosttarget
therapi
includ
broad
applic
multipl
virus
insuscept
drugresist
exampl
hosttarget
treatment
fip
includ
use
cyclosporin
suppress
replic
fipv
cell
cultur
via
inhibit
cyclophilin
critic
host
factor
respons
replic
mani
member
coronavirida
famili
cyclosporin
suggest
pancoronaviru
anoth
exampl
chloroquin
shown
antifipv
antiinflammatori
activ
vitro
reliev
clinic
symptom
fipinfect
cat
compound
howev
pose
safeti
concern
may
inflict
liver
therefor
present
studi
explor
novel
compound
altern
deliveri
approach
toward
facilit
safe
effect
antifipv
drug
develop
diphyllin
new
class
vatpas
inhibitor
herein
appli
inhibit
endosom
acidif
fipv
treatment
vatpas
major
class
cation
transloc
enzym
involv
varieti
vital
process
includ
endocytosi
protein
traffick
metabolit
transport
compound
previous
appli
therapeut
includ
treatment
cancer
leishmaniasi
also
demonstr
hosttarget
treatment
infect
influenza
dengu
virus
reduc
cellular
entri
virus
intercept
endosom
acidif
process
present
studi
valid
compound
antivir
effect
fipv
affirm
compound
broad
applic
antivir
agent
vatpas
present
divers
subunit
isoform
differ
organ
involv
differ
diseas
pathogenesi
transient
tissuespecif
inhibit
vatpas
compound
may
open
new
therapeut
opportun
spite
report
complex
viru
recogn
aciditymedi
endosom
escap
cytosol
entri
essenti
pathway
fcov
life
medium
low
sensit
inhibitor
endosom
acidif
exhibit
serotyp
ii
fcov
cultur
cell
report
regan
et
wherea
serotyp
ii
fcov
cultur
cell
shown
signific
reduct
treat
bafilomycin
consist
takano
et
diphyllin
differenti
role
acid
endocyt
compart
cellular
entri
two
fipv
strain
suggest
lowph
entri
may
straindepend
biotypeindepend
diphyllin
also
exhibit
inhibitori
effect
cultur
cell
ade
infect
supplementari
fig
specul
sensit
dipyllin
exhibit
cell
typeindepend
addit
type
ii
fcov
cultur
cell
found
less
sensit
treatment
viroporin
inhibitor
toward
appli
diphyllin
therapeut
purpos
compound
insolubl
potenti
advers
effect
two
concern
address
use
nanocarri
technolog
nanoparticlebas
drug
deliveri
present
uniqu
advantag
aris
carrier
nanoscal
morpholog
drug
load
capac
approach
appli
extens
anticanc
applic
yield
formul
improv
deliveri
effici
therapeut
recent
nanomedicin
platform
begun
draw
attent
antivir
deliveri
platform
exampl
acyclovir
common
antivir
drug
herp
simplex
viru
deliv
nanocarri
enhanc
efficaci
reduc
side
effect
exhibit
threefold
improv
therapeut
effect
comparison
free
saliphenylhalamid
saliph
vatpas
inhibitor
also
shown
display
enhanc
viral
inhibit
deliv
via
viruslik
dimens
nanoparticl
may
favor
drug
deliveri
site
viral
infect
mani
similar
regard
cellular
entri
vivo
biodistribut
observ
virus
present
studi
pegplga
biocompat
block
copolym
wide
use
drug
deliveri
appli
encapsul
deliveri
diphyllin
nanoparticl
significantli
improv
safeti
efficaci
diphyllin
compound
increas
therapeut
index
approxim
one
infect
model
pronounc
enhanc
attribut
multipl
characterist
nanomateri
firstli
hydrophob
natur
pegplga
nanoparticl
core
facilit
diphyllin
incorpor
obviat
need
organ
solvent
compound
dissolut
result
rather
permeat
cell
aid
dmso
nanocarrierencapsul
diphyllin
reli
nanoparticlemedi
endocytosi
cellular
entri
vatpas
target
diphyllin
ubiquit
among
intracellular
compart
govern
multitud
physiolog
cellular
enhanc
diphyllin
local
insid
endosom
may
thu
reduc
compound
potenti
side
effect
higher
drug
efficaci
improv
cell
protect
nanoformul
also
directli
attribut
enhanc
endosom
drug
deliveri
nanoparticl
higher
effect
dosag
effici
reach
endosom
protein
target
upon
nanoparticl
deliveri
immunerel
diseas
fipv
possess
ade
characterist
contribut
immunopatholog
complic
diseas
prognosi
recognit
fipv
immunecomplex
via
fcr
immun
cell
enhanc
diseas
progress
alter
crossreact
cellular
immun
respons
ineffici
lysi
infect
cell
alter
cellcytokin
respons
collect
promot
ade
although
relationship
serotyp
strain
ade
phenomenon
remain
requir
endosom
acidif
ade
well
studi
demonstr
diphyllin
nanoparticl
possess
dosedepend
antivir
activ
vitro
model
ade
fipv
infect
mimic
diseas
clinic
manifest
attenu
cellular
organel
acidif
nanoformul
effect
inhibit
endosom
acidif
respons
viru
uncoat
cytoplasm
entri
fig
diphyllin
nanoparticl
shown
well
toler
vivo
upon
highdos
intraven
administr
formul
present
promis
treatment
option
lethal
felin
diseas
futur
studi
vivo
anim
model
viral
infect
warrant
diphyllin
vatpas
inhibitor
herein
demonstr
reduc
fipv
infect
inhibit
endosom
acidif
process
requir
viru
uncoat
cellular
entri
diphyllin
pretreat
cell
prior
viral
infect
alter
cellular
suscept
viru
maxim
compound
antivir
activ
enhanc
translat
potenti
antivir
compound
pegplga
nanoparticl
appli
drug
encapsul
deliveri
nanoformul
significantli
reduc
toxic
increas
antivir
effect
diphyllin
enhanc
compound
therapeut
index
vitro
analysi
diphyllin
nanoparticl
potent
inhibit
fipv
infect
vitro
ade
model
anim
studi
diphyllin
nanoparticl
well
toler
follow
intraven
administr
present
work
highlight
diphyllin
diphyllin
nanoparticl
effect
hosttarget
antivir
present
promis
treatment
modal
lethal
infecti
diseas
feli
catu
whole
cell
line
purchas
atcc
maintain
dulbecco
modifi
eagl
medium
supplement
fetal
bovin
serum
penicillinstreptomycinamphotericin
b
cell
line
purchas
bioresourc
collect
research
center
hsinchu
taiwan
maintain
medium
supplement
fetal
bovin
serum
penicillinstreptomycinamphotericin
b
cultur
reagent
purchas
gibco
serotyp
ii
fipv
strain
isol
nation
taiwan
univers
use
studi
virus
propag
titrat
cell
titrat
viral
stock
store
plaqu
assay
cell
seed
plate
cellswel
one
day
prior
experi
right
experi
media
remov
cell
wash
viruscontain
sampl
tenfold
serial
dilut
media
dilut
sampl
ad
cell
incub
hr
media
remov
cell
wash
ml
dmem
contain
methylcellulos
sigma
fb
ad
well
day
plate
fix
formalin
stain
crystal
violet
room
temperatur
min
upon
dri
viral
plaqu
count
plaqueform
unit
pfu
per
ml
viru
determin
fipv
infect
cell
quantit
rtpcr
qrtpcr
use
viru
quantif
briefli
viral
rna
extract
use
viral
nucleic
acid
extract
kit
geneaid
biotech
ltd
taipei
taiwan
cdna
synthes
use
previous
describ
primer
qpcr
perform
use
primer
set
fluoresc
probe
cycl
protocol
thermal
cycler
biorad
cfx
connect
consist
min
preheat
follow
cycl
denatur
min
primer
anneal
extens
plasmid
dna
contain
variou
copi
number
membranenucleocapsid
protein
gene
fipv
use
standard
curv
construct
qrtpcr
viral
load
quantif
two
replic
perform
sampl
standard
diphyllin
chemdiv
san
diego
ca
bafilomycin
sigma
dissolv
dimethyl
sulfoxid
dmso
sigma
nanoparticl
prepar
diphyllin
dissolv
chloroform
mgml
mgml
pegplga
sigma
ml
solvent
mixtur
ad
ml
deioniz
water
probe
sonic
min
sec
result
emuls
place
fume
hood
chloroform
evapor
hr
vehicl
control
empti
pegplga
nanoparticl
prepar
absenc
diphyllin
particl
wash
time
use
amicon
ultra
ml
centrifug
filter
mwco
millipor
g
min
nanoparticl
size
distribut
measur
dl
malvern
instrument
inc
uk
base
manufactur
instruct
wash
particl
resuspend
sucros
store
cell
cellswel
cultur
onto
chamber
slide
nunc
one
day
experi
well
incub
variou
concentr
diphyllin
bafilomycin
min
bafilomycin
use
posit
control
dmso
appli
vehicl
control
acridin
orang
dye
biotium
ad
well
incub
min
wash
fluoresc
imag
obtain
fluoresc
microscopi
red
green
fluoresc
color
acquir
use
texa
red
fitc
filter
respect
fluoresc
intens
greenr
ratio
well
analyz
imagej
cell
seed
plate
densiti
cellswel
day
experi
diphyllin
ad
cell
three
differ
time
point
respect
viru
infect
time
point
includ
hr
prior
infect
time
infect
hr
infect
cell
treat
dmso
prepar
control
viru
inocul
moi
viru
incub
cell
wash
resuspend
fresh
media
contain
diphyllin
h
cellular
supernat
collect
viru
titer
supernat
assess
plaqu
assay
immunofluoresc
stain
perform
valid
antivir
effect
diphyllin
cell
seed
onto
chamber
slide
cellswel
one
day
experi
treat
variou
concentr
diphyllin
hr
cell
infect
moi
well
fix
aceton
min
airdri
room
temperatur
mous
antifcov
monoclon
antibodi
clone
biorad
use
primari
antibodi
stain
fitcconjug
goat
antimous
igg
jackson
lab
use
secondari
antibodi
stain
dapicontain
mount
media
vector
shield
ad
antibodystain
cell
cell
observ
use
fluoresc
microscop
transmiss
electron
microscopi
nanoparticl
sampl
ad
onto
glowdischarg
grid
grid
wash
subsequ
grid
stain
uranyl
acet
sec
excess
stain
remov
filter
paper
grid
airdri
overnight
store
desicc
tem
observ
use
fei
kv
sphera
microscop
fei
tecnai
content
diphyllin
pegplga
nanoparticl
quantifi
hplc
agil
seri
control
pegplga
nanoparticl
particl
load
diphyllin
dissolv
aceton
airdri
nitrogen
sampl
dissolv
mobil
phase
solvent
filter
prior
hplc
ascenti
column
equip
mobil
phase
prepar
use
methanol
water
proport
optim
detect
wavelength
nm
column
temperatur
serial
dilut
sampl
diphylin
dissolv
mobil
phase
solvent
prepar
standard
hplc
analysi
encapsul
effici
ee
diphyllin
calcul
use
formula
ee
encapsul
drugdrug
input
drug
load
yield
calcul
use
formula
load
yield
weight
encapsul
drugtot
polym
weight
vitro
cytotox
diphyllin
diphyllin
nanoparticl
measur
mtt
assay
obtain
confluent
cell
monolay
cell
seed
plate
medium
one
day
experi
cell
treat
differ
concentr
diphyllin
dissolv
dmso
diphyllin
nanoparticl
hr
cultur
supernat
remov
mgml
mtt
solut
bromid
ad
well
cell
cultur
hr
supernat
remov
dmso
ad
well
solubil
purpl
formazan
crystal
min
absorb
measur
nm
nm
use
micropl
reader
untreat
cell
contain
dmso
prepar
repres
cell
viabil
test
diphyllin
nanoparticl
empti
pegplga
nanoparticl
use
vehicl
control
concentr
diphyllin
reduc
cell
viabil
analyz
use
graphpad
prism
graphpad
softwar
san
diego
ca
examin
antivir
effect
diphyllin
diphyllin
concentr
diphyllin
show
inhibit
virusinduc
cpe
assess
use
cell
viabil
assay
briefli
cell
seed
micropl
cellswel
one
day
prior
experi
obtain
confluent
cell
monolay
diphyllin
twofold
dilut
ad
cell
hr
viru
inocul
hr
period
infect
multipl
infect
moi
fipv
well
wash
overlaid
media
contain
diphyllin
concentr
initi
treatment
step
altern
strain
test
use
infect
protocol
moi
anoth
hr
incub
cellular
viabil
examin
mtt
assay
signal
cell
without
infect
diphyllin
treatment
use
repres
cell
viabil
concentr
free
diphyllin
diphyllin
nanoparticl
inhibit
virusinduc
cpe
determin
fit
data
onto
nonlinear
regress
curv
use
graphpad
prism
graphpad
softwar
upon
addit
mab
fipv
infect
enhanc
via
fc
receptor
fcr
set
ade
infect
condit
ml
viral
suspens
pfu
mix
ml
mab
dilut
hybridoma
supernat
centrifug
tube
hr
rotat
subsequ
ml
result
mixtur
inocul
cell
cellswel
plate
pretreat
diphyllin
hr
bafilomycin
use
posit
control
virusantibodi
complex
ad
cell
cocultur
hr
moi
cell
wash
time
reincub
diphyllincontain
fresh
media
hr
later
supernat
well
collect
viral
titer
determin
plaqu
assay
qrtpcr
femal
balbc
mice
intraven
administ
mgml
diphyllin
nanoparticl
diphyllin
twice
day
day
blood
withdrawn
mice
day
nanoparticl
administr
day
day
blood
chemistri
analysi
mice
monitor
sign
distress
chang
bodi
weight
day
anim
protocol
review
approv
institut
anim
care
use
committe
iacuc
nation
taiwan
univers
approv
anim
experi
carri
accord
approv
guidelin
data
analyz
unpair
test
anova
dunnett
multipl
comparison
test
use
graphpad
prism
graphpad
softwar
p
valu
smaller
consid
signific
dataset
gener
current
studi
avail
correspond
author
reason
request
